Navigation Links
Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day
Date:12/7/2009

PINE BROOK, N.J., Dec. 7 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company developing antibody-based therapies for the treatment of life-threatening infectious diseases, announced today that recent animal efficacy and human safety data from the Company's Anthim® anthrax anti-toxin program were presented at the Biomedical Advanced Research and Development Authority (BARDA) Industry Day conference, December 4, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/NY01624LOGO )

In a podium presentation entitled "Advanced Development of Anthim® (ETI-204), a Highly-Effective Monoclonal Antibody for Treatment of Inhalational Anthrax: results of recent safety and efficacy studies," Dr. Leslie Casey, Vice President of Research, presented data from rabbit and primate treatment studies as well as clinical safety studies highlighting the therapeutic potential for Anthim in the treatment of anthrax disease. Using an established non-human primate treatment model, up to 79% of animals treated with a single, intravenous dose of Anthim at the onset of symptoms survived a lethal inhalational challenge with anthrax spores. All animals in this study were bacteremic at time of Anthim treatment.

The Company also reported the results of a previously conducted rabbit treatment study. A single dose of Anthim provided up to 94% survival when administered to rabbits after symptoms of disease were present. The results of these two studies are consistent with previously conducted rabbit and primate studies using Anthim and continue to show the dramatic increase in survival that Anthim can provide.

In a separate dose-escalating human clinical safety study, preliminary results show that Anthim continues to be safe and well-tolerated at doses at or above the anticipated efficacious
'/>"/>

SOURCE Elusys Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Elusys Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
2. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
3. PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop
4. PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop
5. Paloma Pharmaceuticals Presents at the AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics
6. Euro RSCG Life Presents Proprietary Survey Insights at Food and Drug Administration Hearing on Pharmaceutical Promotion via Online and Social Media
7. Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
8. Asthmatx Presents Impact of Bronchial Thermoplasty on Allergy Practices at ACAAI Annual Meeting
9. Dr. Brad Vince, with Vince and Associates Clinical Research, Presents at the Exploratory Development World Congress 2009
10. Caliper Life Sciences Presents LabChip(R) Platform to the U.S. Food and Drug Administration
11. Dr. Julian Henley MD Presents BioMatrix Lift
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... 1, 2015  For many businesses and industries just ... the case, having the right management software can be ... better than software solutions company TraxStar Technologies , ... the company announced the release of the newest version ... "QATrax ...
(Date:4/1/2015)... , April 1, 2015  The U.S. Food ... Sense4Baby™ wireless maternal/fetal monitoring system ... by pregnant patients to self-administer non-stress tests (NST). ... the FDA for use accompanied by medical professionals. ... European Commission in 2013 for self-administration, including the ...
(Date:4/1/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... medical paper has been published describing the positive ... with severe dry eye.  The results met key ... stated that statistically significant differences in both signs ... at various time points throughout the study.  Of ...
Breaking Medicine Technology:TraxStar Technologies Announces Latest QATrax Test Lab Management Software Now Available 2AirStrip Sense4Baby System Receives FDA Clearance for Patient Self-Administration 2AirStrip Sense4Baby System Receives FDA Clearance for Patient Self-Administration 3AirStrip Sense4Baby System Receives FDA Clearance for Patient Self-Administration 4RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea 2RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea 3
... Md., Dec. 19, 2011 Medical imaging has revolutionized healthcare ... injury and disease. Modern equipment and protocols ensure that ... possible amounts of radiation, while still providing accurate results ... imaging and any medical procedure must be balanced with ...
... CAMBRIDGE, Mass., Dec. 19, 2011 At universities, ... ethics review boards tasked with overseeing the protection ... to improve the quality of reviews and research ... tremendous obligation from federal regulation and face intense pressure from ...
Cached Medicine Technology:AAPM Cautions that Patients Should Not Forgo Essential Medical Imaging 2IRBNet Announces 4th Annual IRBNet Ethics in Human Research Protection Award 2IRBNet Announces 4th Annual IRBNet Ethics in Human Research Protection Award 3IRBNet Announces 4th Annual IRBNet Ethics in Human Research Protection Award 4
(Date:4/1/2015)... 01, 2015 BioPlus Specialty Pharmacy ... pharmacies, has released a new app to keep health ... treating chronic hepatitis C virus (HCV) infection. This ‘HCV ... information from the American Association for the Study of ... Numerous new direct-acting oral medications to treat HCV have ...
(Date:4/1/2015)... SCI Solutions , the health industry’s leading ... CEO Joel French will be a featured speaker at ... in Chicago, April 12-16, 2015. French will co-present “ ... Strategies ” with Northeast Georgia Health System (NGHS) on ... 38,000 healthcare industry professionals are expected at the conference, ...
(Date:4/1/2015)... Parents of teenaged and adolescent children might want ... post discusses Teen Violence Related to Substance Abuse. As ... Awareness Month, the substance abuse treatment center has issued ... identify if there may be problems with their kids ... alcohol. , “People learn how to establish healthy relationships ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 Tempaper has ... a new virtual giving campaign that will raise critical ... people fighting muscle disease across the United States. , ... MDA through Tempaperdesigns.com will automatically receive free ... bring strength and urgently needed progress to children and ...
(Date:4/1/2015)... CA (PRWEB) April 01, 2015 ... senior care, today announces the launch of the ... innovative senior care stakeholders and technology companies. The announcement ... Center (NIC) Capital and Business Strategies Forum in ... members, the new Alliance program is now open for ...
Breaking Medicine News(10 mins):Health News:BioPlus Specialty Pharmacy Releases ‘HCV Treatment Path’ App for Hepatitis C Providers 2Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 2Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 3Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 4Health News:Best Drug Rehabilitation Issues Toolkit for Teen Violence Related to Substance Abuse 2Health News:Tempaper and MDA Team up in the Fight Against Muscle Disease 2Health News:Tempaper and MDA Team up in the Fight Against Muscle Disease 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 2Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 4
... of researchers from the University of California, San Diego ... identified two distinct neuronal signaling pathways activated by a ... diseases. One pathway produces the therapeutic benefit; the other ... findings, published in this week,s early online edition of ...
... TUESDAY, Feb. 8 (HealthDay News) -- In pregnant women, even ... higher blood pressure, new research suggests. The study of ... a lead level higher than about 1 microgram per deciliter ... than the safety thresholds set by the U.S Centers for ...
... Feb. 8, 2011 The Muscular Dystrophy Association today ... research to advance understanding of disease processes and to ... other related neuromuscular diseases affecting more than a million ... by generous public support of the MDA Labor Day ...
... 8 (HealthDay News) -- As many as 75 percent of ... have serious consequences for patients, including delayed or missed diagnoses ... analyzed 12 international studies and found that between 20 percent ... percent and 75 percent of tests on emergency care patients, ...
... N.Y. -- University at Buffalo researchers are creating a new and ... Carole Rudra, PhD, UB assistant professor of social and preventive medicine, ... to pollutants in an urban area -- in this case, the ... two-year $440,247 grant from the National Institutes of Health (NIH). ...
... an increase of health inequalities between socio-economic groups has ... World Health Organization, the World Bank and the United ... emphasized its importance and made this issue a priority. ... general health, but have a particular impact on mental ...
Cached Medicine News:Health News:The hitch in the drug? The itch in the drug 2Health News:Lead Exposure May Raise Blood Pressure in Pregnancy 2Health News:MDA awards $13.5 million in grants for research treatments for neuromuscular diseases 2Health News:MDA awards $13.5 million in grants for research treatments for neuromuscular diseases 3Health News:MDA awards $13.5 million in grants for research treatments for neuromuscular diseases 4Health News:New study to use smart phones to track air pollution exposure 2Health News:Income inequalities are increasing the occurence of depression during financial crisis 2
The CA-50 is a compact semi-automated coagulation analyzerproviding 4-parameter random access....
... Advance can reduce costs and ... With its superior ACL technology, ... to use coagulation analyzer that ... the protective transparent cover increases ...
... 100 is an affordable solution ... as a backup analyzer. The ... assays, such as Lupus and ... by superior technology that has ...
B-Hemoglobin test system provide quick, simple and reliable quantitative hemoglobin results. It has unbreakable, disposable cuvette which collect the exact amount of blood and mixes the sample with t...
Medicine Products: